QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Rafarma Pharmaceuticals, Inc. (RAFA) Leads The Charge Against Big Pharma 0 comments
    Aug 23, 2013 1:24 PM

    For years, the worldwide pharmaceutical stage has been dominated by the giant pharmaceutical companies of North America and Europe. With the exception of Japan, now a major player, medicinal drug production has been concentrated in the U.S., Germany, France, and the UK. Given a global market size approaching a trillion dollars, the pharmaceutical market represents an irresistible opportunity that is now being pursued by other parts of world. China and India represent huge markets for lower-end pharmaceuticals, and the African pharmaceutical market is approaching $30 billion. Having hundreds of millions of people dependent upon a relative handful of countries and producers has become a source of concern for many governments.

    In Russia, the government has taken the situation so seriously that it has pursued a number of programs to encourage the growth of its own pharmaceutical industry. In 2010, Russia's then-President Dmitry Medvedev called for measures to further develop the domestic pharmaceutical industry and reduce the country's dependence on foreign medicine. The initiative was echoed a year later by Vladimir Putin. Plans now call for $39 billion in financing in support of biotechnology under the umbrella of what is called the "The Comprehensive Program for Development of Biotechnology in the Russian Federation through 2020."

    Rafarma Pharmaceuticals has been one of the big beneficiaries of this movement, with the immediate result being the construction of the most technologically advanced pharmaceutical plant in Russia. The company has since been accelerating plans to produce a variety of generic pharmaceuticals, all part of the plan to greatly reduce the retail price of the most widely used drugs, freeing the country from the stranglehold of big pharma. Rafarma has, among other agreements, already been contracted for the production of the anti-cancer drug Imatinib and the anti-tuberculosis drug Para-Aminosalicylic Acid, as well as producing its own lines. The company is also actively developing a number of research and distribution agreements.

    For more information, visit Rafarma.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.